New use for autorefractors?

Article

In the future, a standard autorefractor may become useful as a diagnostic tool to screen for contact lens complications.

Baltimore-In the future, a standard autorefractor may become useful as a diagnostic tool to screen for contact lens (CL) complications, said Valerie Seligson, OD, recently. Dr. Seligson is instructor of ophthalmology, The Wilmer Eye Institute at Johns Hopkins University here, and past director of CL services, Kaiser-Permanente, Washington, DC.

How patients were evaluated

"This makes sense because these people don't like to wear glasses and are dependent on their contacts," she said. "Screening would be another way to add a piece to the puzzle in making our diagnostic and therapeutic decisions in such patients a little easier."

The autorefractor is a computer that measures how light is changed as it enters the eye, and is used to provide an objective measurement of a patient's refractive error.

"It is quick, simple, and painless. Most ODs have one in their office, and the measurements are usually performed by a technician," Dr. Seligson said, adding that the autorefractor confidence score (AR score) helps determine the validity of the refractive error, but is also a measure of light intensity.

"On the NIDEK, as an example, the value of 9 represents a very reliable refraction. The scale is from 9 (reliable) to 5 (not a valid finding)," she explained. "A decrease in the signal strength (a low score) can indicate CL distortion, filming, or deposits, an opacity on either the lens or the cornea. It is a possible red flag for patients with no symptoms."

A different application

Dr. Seligson and colleagues at Johns Hopkins conducted a pilot study in which they used the autorefractor to evaluate complications in soft CL wearers. They included 40 consecutive patients who came in for a routine exam and were wearing their soft contacts.

The AR score was correlated with the subject's best-corrected visual acuity (BCVA) with contact lenses, BCVA with manifest refraction, subjective comfort, and slit-lamp exam.

Thirty-six of these 40 patients scored a 9 on the autorefractor, and had no CL issues. Two of the 40 scored a 9 but had problems, including red eye with infection, contact lens overwear with injection, and superficial punctate keratitis.

Two of the 40 had definite decreased vision with slight irritation and redness. Both patients scored a 6 for AR confidence.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.